Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
Completed
NCT01505790
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
187
Enrollment(s)
1
Study location(s)
Interventional (Phase III)
Acute Coronary Syndromes
Unknown status
NCT01598337
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
200
Enrollment(s)
1
Study location(s)
Interventional (Phase III)
Coronary Artery Disease
Completed
NCT01256476
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
328
Enrollment(s)
0
Study location(s)
Interventional (Phase IV)
Primary Dyslipidemia
Mixed Dyslipidemia
Completed
NCT01167023
Prasugrel Versus Placebo in Adult Sickle Cell Disease
62
Enrollment(s)
14
Study location(s)
Interventional (Phase II)
Sickle Cell Anemia
Completed
NCT00245388
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
330
Enrollment(s)
54
Study location(s)
Interventional (Phase II|Phase III)
Dyslipidemia
Completed
NCT00834600
Renin Profiling in Selection of Initial Antihypertensive Drug
185
Enrollment(s)
5
Study location(s)
Interventional (Not Applicable)
Hypertension
Unknown status
NCT01441908
Longitudinal Study of Multi-Analyte Profile for Dyslipidemia
40
Enrollment(s)
1
Study location(s)
Interventional (Not Applicable)
Dyslipidemia
Completed
NCT01463163
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
50
Enrollment(s)
1
Study location(s)
Interventional (Phase IV)
Platelet Reactivity
91
92
93
94
95